|
Baseline characteristics including outliers (all randomizedpatients)
|
|
n
|
33
|
32
| |
|
Female proportion [n (%)]
|
11 (33.3%)
|
10 (31.2%)
|
0.534
|
|
Mean age in years [mean (SD)]
|
10.0 (3.1)
|
10.6 (2.9)
|
0.403
|
|
GINA level 2 [n (%)]
|
26 (78.8%)
|
26 (81.2%)
|
0.525
|
|
GINA level 3 [n (%)]
|
7 (21.2%)
|
6 (18.8%)
|
|
Mean peak flow in l/min [mean (SD)]
|
296 (101)
|
315 (91)
|
0.444
|
|
Mean annual costs for allergic-drugs before intervention onset in euro[mean (SD)]
|
434 (332)
|
296 (220)
|
0.130
|
|
Mean annual costs for non-allergic-drugs before intervention onset ineuro [mean (SD)]
|
51 (87)
|
50 (98)
|
0.571
|
|
Mean total annual drug costs before intervention onset in euro [mean(SD)]
|
485 (377)
|
345 (245)
|
0.083
|
|
Baseline characteristics without outliers (all analysedpatients)
|
|
n
|
28
|
31
| |
|
Female proportion [n (%)]
|
8 (28.6%)
|
10 (32.3%)
|
0.785
|
|
Mean age in years [mean (SD)]
|
10.4 (3.2)
|
10.8 (2.8)
|
0.628
|
|
GINA level 2 [n (%)]
|
21 (75.0%)
|
25 (80.6%)
|
0.417
|
|
GINA level 3 [n (%)]
|
7 (25.0%)
|
6 (19.4%)
|
|
Mean asthma level GINA [mean (SD)]
|
2.25 (0.441)
|
2.19 (0.402)
|
0.755
|
|
Mean peak flow in l/min [mean (SD)]
|
308 (105)
|
317 (91)
|
0.727
|
|
Mean annual costs for allergic-drugs before intervention onset in euro[mean (SD)]
|
315 (180)
|
273 (183)
|
0.443
|
|
Mean annual costs for non-allergic-drugs before intervention onset ineuro [mean (SD)]
|
33 (54)
|
48 (99)
|
0.974
|
|
Mean total annual drug costs before intervention onset in euro [mean(SD)]
|
349 (192)
|
322 (209)
|
0.627
|
